22.95
Schlusskurs vom Vortag:
$21.64
Offen:
$21.85
24-Stunden-Volumen:
260.10K
Relative Volume:
0.47
Marktkapitalisierung:
$1.32B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.61%
1M Leistung:
+19.48%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Omada Health Inc Stock (OMDA) Company Profile
Firmenname
Omada Health Inc
Sektor
Branche
Telefon
888-987-8337
Adresse
500 SANSOME STREET, SAN FRANCISCO
Vergleichen Sie OMDA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
OMDA
Omada Health Inc
|
22.95 | 1.21B | 0 | 0 | 0 | 0.00 |
![]()
VEEV
Veeva Systems Inc
|
295.15 | 46.60B | 2.86B | 780.66M | 1.19B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
73.51 | 13.19B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
68.30 | 12.44B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
88.59 | 7.56B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
37.14 | 6.26B | 906.14M | -52.62M | 89.62M | -0.3621 |
Omada Health Inc Stock (OMDA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-01 | Eingeleitet | Barclays | Overweight |
2025-07-01 | Eingeleitet | Canaccord Genuity | Buy |
2025-07-01 | Eingeleitet | Evercore ISI | Outperform |
2025-07-01 | Eingeleitet | Goldman | Buy |
2025-07-01 | Eingeleitet | JP Morgan | Overweight |
2025-07-01 | Eingeleitet | Morgan Stanley | Overweight |
2025-07-01 | Eingeleitet | Needham | Buy |
Alle ansehen
Omada Health Inc Aktie (OMDA) Neueste Nachrichten
Omada Health shares rise 3.31% intraday after announcing participation in Morgan Stanley's Global Healthcare Conference. - AInvest
Virtual Healthcare Leader Omada Health to Present at Morgan Stanley's 23rd Global Healthcare Conference - Stock Titan
Healthcare Analysts Bullish on CSL, UnitedHealth, and Omada Health - AInvest
Omada Health stock rises on market debut - MSN
U.S. Digital Therapeutics Market Positioned for Accelerated - openPR.com
Digital health Q2 earnings: New guys win, GLP-1 companies lose - Modern Healthcare
Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Gilead Sciences (GILD) and Cytokinetics (CYTK) - The Globe and Mail
Omada Health, Inc.: Strong Market Position and Growth Potential Justify Buy Rating - TipRanks
Omada grows revenue, membership in public earnings debut - Healthcare Dive
Omada Health 2025 Q2 Earnings Losses Narrow Sharply, 50% Year-Over-Year Reduction in Net Loss - AInvest
Omada Health revenue jumps 49% year-over-year post-IPO - TechTarget
Goldman Sachs raises Omada Health stock price target to $31 on strong Q2 By Investing.com - Investing.com South Africa
Goldman Sachs raises Omada Health stock price target to $31 on strong Q2 - Investing.com Nigeria
Barclays raises Omada Health PT to $24, maintains Overweight rating. - AInvest
Freedom Broker lowers Omada Health stock price target to $20 from $26 - Investing.com India
Freedom Broker lowers Omada Health stock price target to $20 from $26 By Investing.com - Investing.com South Africa
Omada Health price target raised to $28 from $27 at Canaccord - TipRanks
Omada Health price target raised to $24 from $21 at Barclays - TipRanks
Omada Health Reports Strong Q2 2025 Growth - TipRanks
Omada Health reports Q2 EPS (24c), consensus (13c) - TipRanks
Omada Health beats on revenue in first earnings report since IPO - CNBC
Omada Health Reports Second Quarter 2025 Results - The Manila Times
Earnings Flash (OMDA) Omada Health, Inc. Reports Q2 Revenue $61.4M, vs. FactSet Est of $55.3M - MarketScreener
U.S. Digital Therapeutics Market to Witness Remarkable Growth - openPR.com
Omada Health, Inc. (NASDAQ:OMDA) Receives $23.86 Average PT from Analysts - Defense World
Omada Health’s Strategic Partnerships and AI Leverage Drive Growth and Profitability Outlook - TipRanks
Health Coach Market is evolving rapidly Through 2025 To 2032 | Noom, Inc., HealthifyMe, Omada Health - openPR.com
Digital Therapeutics for Diabetes Market is projected to reach - openPR.com
Omada Health: Long Growth Runway Ahead - Seeking Alpha
Omada Health: A Buy Rating for a Company with Strong Distribution Partnerships and Clinical Validation - AInvest
Omada Health Sets Q2 Earnings Date: Virtual Healthcare Leader Reports August 7 - Stock Titan
Interleukin Inhibitors Market Generated Opportunities, Future Scope by 2032 | Noom, Inc., HealthifyMe, Omada Health - openPR.com
Omada Health, Inc.: A Promising Buy Amid Technical Weakness and Growth Potential - TipRanks
IPO market remains 'sluggish' despite recent San Francisco listings - The Business Journals
EQBK issues 1.73M shares, completes NBC merger & adds new director | OMDA SEC FilingForm 4 - Stock Titan
More than $16B in med-tech funding raised through 1H25 - BioWorld MedTech
The Making of Omada Health | Omada Health Co-Founder & CEO Sean Duffy - iHeart
These are the 9 healthcare startups next in line to go public, according to bankers and investors - Business Insider
Omada Health IPO signals healthier market, avoids ‘down-round’ trend - MSN
Health Coach Market Set to Witness Significant Growth by 2025-2032 | Noom, Inc., HealthifyMe, Omada Health - newstrail.com
Omada Health Stock (OMDA): A Growth Story in Digital Health - Value The Markets
Omada Health stock initiated with Buy rating at Freedom Broker - Investing.com
Needham initiates coverage on Omada Health stock with Buy rating By Investing.com - Investing.com India
Omada Health initiated with a Buy at Needham - TipRanks
Omada Health initiated with an Overweight at JPMorgan - TipRanks
Omada Health initiated with an Overweight at Morgan Stanley - TipRanks
Omada Health initiated with an Overweight at Barclays - TipRanks
Don’t expect a wave of digital health IPOs quite yet - Modern Healthcare
Omada Health initiated with a Buy at Goldman Sachs - TipRanks
Omada Health: A Compelling Investment Opportunity in Digital Health with Strong Growth Potential - TipRanks
Finanzdaten der Omada Health Inc-Aktie (OMDA)
Es liegen keine Finanzdaten für Omada Health Inc (OMDA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):